the tissues. The short range (5-9 mm) of the a and lithium-7 particles released from the boron-10 (neutron, a) lithium-7 neutron capture reaction makes the microdistribution of boron-10 critically important in therapy. 7 The release of these particles constitutes high linear energy transfer radiation. These characteristics contribute to tumor-selective and strong tumoricidal activity with minimal damage to normal tissue. If sufficient quantities of boron compounds can be made to accumulate selectively in the tumor tissues, BNCT becomes an ideal intensive particle radiotherapy.
The concept of this unique particle radiation therapy with selective uptake of a suitable isotope was first introduced by Locher in 1936 . 19 The first clinical trial of BNCT for patients with glioblastoma was reported by Farr et al. in the 1950s. 10 However, the previously used version of BNCT suffered from numerous problems: a lack of neutron penetration, especially for deep-seated tumors; insufficient contrast in boron concentration between tumor and normal tissues; an absolute lack of boron in tumor tissues; and uncertain estimation of the neutron flux captured by the boron-10 atoms in tumor cells. We modified several parts of the procedure to resolve these problems and applied the modified BNCT to the treatment of malignant gliomas. 21 In addition, we reported the effectiveness of BNCT for high-grade meningiomas, with special reference to tumor shrinkage, as a case report and an early case series. 23, 32 Now that we have treated 20 patients with high-grade meningioma by BNCT, and observed these patient for more than 1 year, we share further details in this paper, not only about the tumor volume reduction, but also about long-term control rate, including cumulative survival data and treatment failure patterns.
Methods

Patient Population
Twenty patients with recurrent high-grade meningioma were treated with BNCT in the Department of Neurosurgery at Osaka Medical College between June 2005 and September 2011. We report the results from these 20 patients, all of whom were followed up for more than 1 year. The cases consisted of 12 anaplastic, 4 atypical, 2 papillary, and 1 rhabdoid meningioma, and 1 sarcoma that began as an anaplastic meningioma. Patient profiles are detailed in Table 1 . All cases were referred to our institute for BNCT due to uncontrolled tumor growth after repetitive surgeries and EBRT or SRS. These patients had already undergone treatment by EBRT alone in 4 cases, by SRS or SRT alone in 13 cases, and by a combination of both in 3 cases.
Fluorine-18-Labeled BPA PET Analysis
The patients underwent 18 F-BPA PET to assess the distribution of BPA and to estimate the boron concentration in tumors before neutron irradiation. 15, 16, 21, 23, 32 Notably, BPA is itself a therapeutic boron compound. The tumor-to-normal-brain ratio of BPA uptake can be estimated from 18 F-BPA PET, and subsequent dose planning is based on this ratio; each ratio of the patients is included in Table 1 . The PET study had to be omitted in 1 case of anaplastic meningioma (Case 3) because of machine malfunction.
Clinical Regimen of BNCT for Malignant Meningiomas
This project was approved by the Ethical Committee of Osaka Medical College, and each candidate was also discussed and approved by the board of reviewers at Osaka Medical College and Kyoto University Research Reactor Institute. The clinical regimen of BNCT for malignant meningiomas was modified slightly from that for malignant gliomas. 21 Patients were typically administered 500 mg/kg of BPA with or without 5 or 2.5 g of BSH (Katchem Ltd) per person. Boronophenylalanine was kindly supplied by the Stella Pharma Corporation in the initial cases and afterward was purchased mainly from Interpharma Praha, a.s. As the study period progressed, BSH became difficult to obtain due to its exorbitant cost. Thus, BSH administration was omitted from Cases 7 through 20.
Boronophenylalanine was administered in the 2 hours just prior to neutron irradiation (200 mg/kg/hr) and then during neutron irradiation (100 mg/kg/hr). This administration method was adopted to maintain a steady blood BPA concentration throughout the entire neutron irradiation. When BSH was available, the compound solution was administered for 1 hour, starting at 12 hours prior to neutron irradiation. The boron concentration in the blood was monitored by sampling every 1 to 2 hours after boron compound administration until neutron irradiation was completed. The boron concentrations from BSH in the tumor and brain tissue were assumed to be the same as the blood concentration. The boron concentrations from BPA in the tumor and normal brain were estimated from the tumor-to-normal-brain ratio of 18 F-BPA on PET. Judging from the contribution of each boron compound and the relative biological effectiveness of neutron beams and compounds described previously, 24,25 the neutron fluence rate was simulated by the dose-planning system SERA (Simulation Environments for Radiotherapy Applications; Idaho National Engineering and Environmental Laboratory), and the total doses to the tumor and normal brain were estimated. The duration of neutron irradiation was determined not to exceed 15 Gy-Eq to the normal brain. In this instance, Gy-Eq (Gray Equivalent) means an x-ray dose that can provide biologically equivalent effects to total BNCT radiation. After the treatment, the doses given were precisely reestimated.
Assessment of Effectiveness
The effectiveness of this treatment was volumetrically assessed in serial radiographic analysis. The Gd-contrasted lesion on MRI was semiautomatically selected, and the area was measured on each slice based on the contrast cutoff value (increased intensity on MRI by Gd) from the background. The value of the area was calculated as tumor volume by adding the areas of all slices using I-Response software (Cedara Corp.). Based on the diagnostic images before BNCT, the relative values of the tumor volume (percentage of control) were calculated from consecutive images obtained in each patient's follow-up evaluation. Then, changes in these values over time were graphed and investigated for trends among our 20 patients with high-grade meningiomas undergoing BNCT.
Survival Analysis
Patient survival was defined in 2 ways: the number of months survived after diagnosis of high-grade meningioma and the number after the application of BNCT.
Results
Absorbed Dose in Tumor Tissue
The duration of irradiation was planned to not exceed 15 Gy-Eq in normal brain tissue. The absorbed dose to the tumor tissue was dependent on both the boron concentration in the tumor tissue and the neutron irradiation time, which varied in each case. Therefore, the absorbed dose to the tumor tissue in our protocol was not uniform from case to case. The mean maximum and minimum absorbed doses in our series were 73.4 Gy-Eq (95% CI 65.6-81.3 Gy-Eq) and 33.3 Gy-Eq (95% CI 26.9-39.9 Gy-Eq), respectively (Table 1) . These absorbed doses were administered not in fractionation but in 1-time irradiation in BNCT.
Volume Reduction of the Treated Mass During Follow-Up
As we reported previously, all of the initial case series (Cases 1-7) showed volume reduction of the mass during the observation. 23, 32 In Fig. 1 we show representative volume reductions of the treated masses from more recent cases (Cases 14, 17, 18, and 20). All other treated tumors also showed definitive shrinkage during followup; this tendency toward volume reduction is illustrated in Fig. 2 . Although all tumors showed a trend of gradual reduction in volume, a transient increase after BNCT was observed in some cases, usually within a month of treatment, before decreasing; this pattern was called pseudoprogression. The mean tumor size prior to BNCT was 52.2 cm . A mean volume reduction of 64.5% was achieved within only 2 months of BNCT (Fig. 2) .
Treatment Failure
Among the 20 cases of high-grade meningioma treated by BNCT, 6 cases demonstrated systemic metastasis, including lung, vertebral bone, clavicle, liver, and lymph node metastasis ( Table 2 ). Four of these 6 patients died from these metastatic lesions and not the original intracranial lesions. A typical systemic metastasis is depicted in Fig. 3 (Case 13, A-D; Case 7, E-H). Figures 3A and B show good local control of the anaplastic meningioma over the first 3 years, compared with the patient's repeated local tumor recurrence every few months prior to BNCT, even with repetitive SRS treatment. This patient died due to lung metastasis (Fig. 3D) . Prior to BNCT, the patient had had a metastatic lesion in the left clavicle, which was controlled by EBRT for 3 years during the observation period. Also in this case, we experienced tumor recurrence out of the field of neutron irradiation (Fig. 3C) . In Case 7, in which anaplastic meningioma developed into sarcoma, there was continuous tumor shrinkage during the 7 months of follow-up ( Fig. 3E and F) . This patient developed liver metastasis (Fig. 3G) , and died due to dyspnea from the lung metastasis (Fig. 3H) . Unfortunately we had no chance to verify that the histological diagnosis of the metastatic lesions was the same as that of the original high-grade meningioma.
Seven of the 20 BNCT-treated high-grade meningioma cases showed recurrence outside the field of neutron irradiation (Table 2) . A representative recurrence outside the field of neutron irradiation is depicted in Fig. 3C ; this lesion was discovered incidentally 33 months after BNCT. We did not apply a second BNCT for this recurrent lesion because multiple metastases had already been identified in the lung. One patient (Case 14, atypical meningioma) chose to abandon further treatment because of financial difficulties and died due to the metastatic lesion.
Three of the 20 cases experienced increased intracranial pressure by intractable hydrocephalus due to CSF dissemination (Table 2 ). This type of hydrocephalus could not be controlled by a shunting operation due to the viscosity of the CSF. Typical images are depicted in Fig.  3I -K (Case 11, anaplastic meningioma).
Only 3 of 20 patients died due to local tumor progression ( Table 2) . Two of these 3 local tumor progression cases were complicated with symptomatic radiation necrosis.
Survival Analysis After Diagnosis and BNCT
The median follow-up duration was 13 months. Six patients are still alive; at present, the median survival times after BNCT and diagnosis are 14.1 months (95% CI 8.6-40.4 months) and 45.7 months (95% CI 32.4-70.7 months), respectively (Fig. 4) . It is rather difficult to compare our results to other reports 28 because our patients were refractory to any existent treatments; therefore our study sample was biased due to multiple treatments with repetitive surgeries and radiotherapies (Table 1) . Also, many patients in our study died due to systemic metastasis and recurrence outside of the radiation field, as noted above (Table 2) . 
Discussion
In this report, we present evidence of favorable local control of high-grade meningiomas using BNCT. Only 3 patients died due to local treatment failure, although the follow-up observation periods were rather brief in several recent cases. However, irrespective of good local control of high-grade meningiomas by BNCT, many patients died and the median patient survival time in high-grade meningiomas after BNCT was 14.1 months (Fig. 4) . The most prominent pattern of treatment failure in our series was intracranial distant recurrence outside the radiation field, experienced in 7 of 20 cases. The other patterns of treatment failure were systemic metastasis in 6 cases and CSF dissemination in 3 cases. Given that the reported incidence of CSF dissemination in meningioma is only 2%, 5 our series shows a rather high incidence rate. With regard to systemic metastasis in high-grade meningioma, such high incidences have been previously reported in the literature. 5, 9 We are not entirely sure of the reason for this high incidence of systemic metastasis. It may be possible that the treatmentrefractory nature of our cases resulted in a selection bias for aggressive care and longer survival. Overall, the high incidences of out-of-field recurrence, CSF dissemination, and systemic metastasis might be ascribed to the advanced stage of the patients in our series, as all cases were referred to us after the failure of local tumor control, even using repetitive surgeries and radiotherapies. This selection bias for refractory cases makes it difficult to compare our treatment failure results with the incidence rates reported in the literature. Our patients' advanced tumor stage also makes it difficult to compare the survival data with that of other treatments. All high-grade meningioma cases in this series were recurrent, complicated cases. Historically, conventional EBRT was first used to treat high-grade meningiomas, but with unsatisfactory results.
20
In our series, the original high-grade meningiomas were not controlled locally by EBRT alone. Thereafter, SRS was used for the treatment of high-grade meningiomas, as reported in the literature. 13, 27, 29, 31 The gross tumor volume treated by SRS in these studies was relatively small in comparison with that in our series. Additionally, in our series, 9 patients had already received repetitive SRS but experienced recurrence nonetheless. The typical treatment failure pattern of high-grade meningiomas by SRS in our series was marginal recurrence at the SRS fields. Even for these SRS-refractory cases, BNCT was able to provide good local tumor control.
Particle radiotherapies using proton beams 2, 6, 14, 26, 30, 33 and carbon ion beams 8, 30 have been more recently applied to cases of high-grade meningioma. Again, it is very difficult to compare our data to the data from particle radiotherapies. First, almost all reported series, including our own, have comprised a limited number of cases. The protocols have varied as well: in some studies, particle therapy was applied just after surgery as the initial radiotherapy, and in others it was applied at recurrence. The applied doses varied and in some trials, particle radiation was followed by fractionated EBRT. In addition, the data on tumor shrinkage after particle irradiation have been scarce. There has been only 1 preliminary report addressing this subject, and the results indicated no prominent early tumor shrinkage using proton and carbon ion beams for the treatment of high-grade meningiomas.
30
One of the advantages of BNCT is that the radiation field may be planned rather more ambiguously than in SRS and other particle radiotherapies. This merit of BNCT might decrease recurrence in the peri-irradiated field in comparison with other radiation techniques, even with the same absorbed dose as described as "Gy-Eq." Encouragingly, almost all masses in our series responded well, with rapid shrinkage after BNCT (Figs. 2 and 3) , as also reported elsewhere. 23 This rapid shrinkage might contribute to the prompt recovery of symptoms in some cases. Our patient in Case 1 became ambulatory 1 week after BNCT, and our patient in Case 7 experienced relief from facial pain within 2 weeks of BNCT, as reported previously.
23,32
In BNCT, most potent antitumor effects are caused by particles, and we applied 33.3 Gy-Eq and 73.4 Gy-Eq for tumor tissue as minimum and maximum 1-time tumor doses, respectively (Table 1 ). In the literature on particle radiation, some clinical trials have used proton or carbon particle doses between 18 Gy-Eq and 56 Gy-Eq with fractionation. 8, 33 The difference in tumor shrinkage between a and lithium particles and other particles such as carbon and protons may be ascribed to the difference of linear energy transfer. The linear energy transfer of a and lithium particles is higher than that of both protons and carbon particles. It is widely accepted that high linear energy transfer particles have greater biological effects than low linear energy transfer particles; 1,3 of course, there might be other causes. For example, in BNCT a large dose can be delivered at a single time, while other particles are usually applied with fractionation and additional low linear energy transfer EBRT. Because of this difference in protocol, other particles might have less impact on tumor shrinkage.
With respect to adverse effects of BNCT, we experienced 6 cases of symptomatic radiation injury among our 20 cases. One instance was the occurrence of subacute brain swelling after BNCT, as reported previously, 23 while the other 5 cases appeared to show radiation necrosis. Because all cases were introduced to our institute after intensive radiotherapies prior to BNCT, radiation necrosis may have been inevitable, despite the tumor-selective nature of BNCT. Recently, we applied BNCT to a patient with a high-grade meningioma who had never been treated with any radiotherapy, and are now observing this case carefully. Bevacizumab has shown potent effects treating symptomatic radiation necrosis in the brain, 12 , 18 and we have applied this drug for symptomatic radiation necrosis after BNCT for malignant gliomas. 11 This strategy should be applicable and effective for the treatment of radiation necrosis after BNCT for high-grade meningiomas.
We should emphasize that we found pseudoprogression after BNCT in at least 3 of our 20 high-grade meningioma cases. As we described previously, 22 this phenomenon could itself be an indicator of how promising and intensive the effects of this treatment are.
Conclusions
Boron neutron capture therapy is a new treatment concept and method that has already been used on malignant gliomas, including glioblastomas. Our study suggests that high-grade meningiomas may be an even better candidate for BNCT than those lesions. The meningiomas in our series were somewhat superficial (located on the surface of the brain), except for some specific situations at the skull base, which is advantageous to neutron penetration.
With regard to BPA accumulation, high-grade meningiomas showed a good ratio of tumor to normal brain, even compared with malignant gliomas (Table 1 ). In addition, judging from the rapid shrinkage of the mass, our assumption about the compound biological effectiveness of BPA for high-grade meningioma-which was assumed to be equal to that of glioblastoma-might have been an underestimation; the real value might be higher than that for glioblastoma. If we can apply BNCT for high-grade meningioma as the initial radiotherapy or at least at the first recurrence, rather than at such advanced stages, more favorable results than those described in our study might be obtained, such as avoiding systemic metastasis or outof-field recurrence.
